Ga. Comp. R. & Regs. r. 480-11-.02. Compounded Drug Preparations.

GeorgiaRegulations

Ask Donna

How this section applies to your facts.

Rules and Regulations of the State of Georgia › Department 480 RULES OF GEORGIA STATE BOARD OF PHARMACY › Chapter 480-11 PHARMACEUTICAL COMPOUNDING. › Ga. Comp. R. & Regs. r. 480-11-.02

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

(1) Compounded drug preparations - Pharmacist/Patient/Prescriber Relationship.

(a) Based on the existence of a pharmacist/patient/prescriber relationship and the

presentation of a valid prescription drug order or in anticipation of a prescription

drug order based on routine, regularly observed prescribing patterns, pharmacists

may compound, for an individual patient, drug preparations that are not

commercially available in the marketplace or commercially available in the place

as outlined by the restrictions under 12(b). Dispensing of pharmaceutical products

shall be consistent with the provisions of O.C.G.A. T. 16, Ch. 13 and T. 26, Ch. 4

relating to the issuance of prescriptions and the dispensing of drugs.

(b) Pharmacists shall receive, store, or use pharmaceuticals that have been

manufactured or repackaged in a FDA-registered facility. Pharmacists shall also

receive, store, or use pharmaceuticals in compounding preparations that meet

official compendia requirements. If neither of these requirements can be met,

pharmacists shall use their professional judgment to procure alternatives.

(c) Pharmacists may compound pharmaceuticals prior to receiving a valid prescription

drug order based on a history of receiving valid prescription drug orders within an

established pharmacist/patient/prescriber relationship, and provided that they

maintain the prescriptions on file for all such preparations compounded at the

pharmacy. Preparations compounded in anticipation of a valid prescription drug

order shall be properly labeled to include the name of the compounded

pharmaceutical, date of compounding, and beyond-use date.

(d) The distribution of non-patient specific compounded preparations for office use by

a practitioner, excluding veterinarians, is prohibited. This subsection shall not

affect 503b outsourcing facilities ability to provide non-patient specific

compounded preparations for office use by a practitioner. The distribution of

compounded preparations, for office administration or emergency dispensing, to a

veterinarian shall not exceed 5% of production of compounded preparation in a

calendar year by that pharmacy. Amounts produced greater than 5% shall be

considered manufacturing and will require separate licensure as a manufacturer.

1. "Emergency Dispensing" shall mean no more than a 10-day supply

dispensed for an urgent condition to an animal patient by a licensed

veterinarian with a valid veterinarian-client-patient relationship when timely

access to a compounding pharmacy is not available.

(e) Pharmacists must maintain a separate compounding log for each compounded

preparation that includes the quantity and amount of each pharmaceutical that is

compounded. Pharmacists shall label all compounded preparations that are

dispensed pursuant to a prescription in accordance with the provisions of

O.C.G.A. T. 16, Ch. 13 and O.C.G.A. T. 26, Chs. 3 and 4, and Board rules and

regulations, and shall include on the labeling an appropriate beyond-use date as

determined by the pharmacist in compliance with USP-NF standards for pharmacy

compounding.

(f) All compounded preparations labeled in accordance with Board rules and

regulations regarding pharmaceutical compounding shall be deemed to meet the

labeling requirements of O.C.G.A. T. 16, Ch. 13, and T. 26, Chs. 3 and 4.

(2) Compounded drug preparations - Pharmacist for Distribution to Veterinarian.

(a) Only a pharmacy licensed or registered by the Board may distribute compounded

preparations to veterinarians licensed in this state for administration or emergency

dispensing to their patients in the course of their professional practice, either

personally or by an authorized person under their direct and immediate

supervision.

(b) A veterinarian shall make a request to the pharmacy for a compounded preparation

in the same manner as ordering products from a wholesale pharmaceutical

distributor or manufacturer and not by using a prescription drug order.

(c) A pharmacy receiving an order from a veterinarian for a compounded preparation

shall maintain such order with its compounding records as required in Rule 480-

11-.08 and other rules and regulations of the Board.

(d) Pharmacists shall label all compounded preparations distributed to veterinarian for

administration or emergency dispensing to their patients with the following:

1. "By purchase order, Not by prescription",

2. "For Office Use Administration or Emergency Dispensing by a Veterinarian

Only - Not for resale",

3. The name of the active ingredients and strengths contained in the

compounded preparation,

4. The lot number or identification of the compounded preparation,

5. The pharmacy's name, address and telephone number,

6. The initials of the pharmacist verifying the finished compounded

preparation and the date verified,

7. The quantity, amount, size, or weight of the compounded preparation in the

container,

8. An appropriate beyond-use (expiration) date of the compounded preparation

as determined by the pharmacist in compliance with Board rule and USP-

NF standards for pharmacy compounding, and

9. Appropriate ancillary instructions such as storage instructions or cautionary

statements, and where appropriate, hazardous drug warning labels.

(e) Pharmacists shall enter into a written agreement with a veterinarian for the

veterinarian's use and emergency dispensing of the compounded preparation

before providing any compounded preparation to the veterinarian. The written

agreement shall provide the following information:

1. The name and address of the veterinarian, license number and contact

information.

2. An agreement by the veterinarian that the compounded preparation may

only be administered to the patient and may not be dispensed to the patient

or sold to any other person or entity except for a case in which emergency

dispensing is required.

3. An agreement by the veterinarian to include on the patient's chart, or

medication administration record the lot number and beyond-use date of the

compounded preparation administered or dispensed to the patient.

4. The procedures for a patient to report an adverse reaction or to submit a

complaint about a compounded preparation.

5. The procedure to be used when the pharmacy has to recall a batch of

compounded preparation.

(f) When pharmacists are compounding preparations to be provided to veterinarians

for use in patient care or when pharmacists are altering or repackaging such

products for veterinarians to use in patient care in the veterinarian's office, the

compounding shall be conducted as allowed by applicable federal law and Board

rules and shall be in compliance with USP-NF standards for compounding.

(g) Pharmacists may not compound Schedule II, III, IV or V controlled substances, as

defined in Article 2 of Chapter 13 of Title 16 without a patient specific

prescription drug order.

(h) Nothing in this paragraph shall be construed to apply to pharmacies owned or

operated by institutions or to pharmacists or practitioners employed by an

institution or its affiliated entities; provided, however, pharmacies owned or

operated by institutions and pharmacists and practitioners within or employed by

institutions or affiliated entities shall remain subject to the other rules and

regulations of the Board governing the compounding of pharmaceuticals.

(3) Pharmacists must maintain documentation of proof that the beyond-use date on

compounded pharmaceuticals is valid.

(4) Pharmacists shall personally perform or personally supervise the compounding process,

which shall include a final verification check for accuracy and conformity to the formula

of the product being prepared, correct ingredients and calculations, accurate and precise

measurements, appropriate conditions and procedures, and appearance of the final

product.

(5) Pharmacists shall ensure compliance with USP-NF standards for both sterile and non-

sterile compounding.

(6) Pharmacists may use prescription bulk substances in compounding when such bulk

substances:

(a) Comply with the standards of an applicable USP-NF monograph, if such

monograph exists, including the testing requirements, and the Board rules on

pharmaceutical compounding; or are substances that are components of

pharmaceuticals approved by the FDA for use in the United States; or otherwise

approved by the FDA;

(b) Are manufactured by an establishment that is registered by the FDA; and

(c) Are distributed by a wholesale distributor licensed by the Board and registered by

the FDA to distribute bulk substances if the pharmacist can establish purity and

safety by reasonable means, such as lot analysis, manufacturer reputation, or

reliability of the source.

(7) Pharmacists shall maintain records of all compounded pharmaceutical products.

Pharmacist shall maintain a complete compounding formula listing all procedures,

necessary equipment, necessary environmental considerations, and other factors in detail

when such instructions are necessary to replicate a compounded product or where the

compounding is difficult or complex and must be done by a certain process in order to

ensure the integrity of the finished product.

(a) This record-keeping requirement does not apply when FDA-approved and labeled

sterile injectable drug products, produced by registered pharmaceutical

manufacturers, are reconstituted under conditions as allowed by USP 797, and

each such sterile drug product must be administered within 24 hours of being

reconstituted.

(8) Pharmacists engaged in the compounding of pharmaceuticals shall operate in

conformance with Georgia laws and regulations. Non-sterile compounded preparations

shall be subject to USP 795. All sterile compounded preparations shall be subject to USP

797.

(9) Radiopharmaceuticals. If radiopharmaceuticals are being compounded, conditions set

forth in the Board's rules for nuclear pharmacists and pharmacies must be followed.

(10) Special precaution preparations. If drug preparations with special precautions for

contamination are involved in a compounding operation, appropriate measures,

including either the dedication of equipment for such operations or the meticulous

cleaning of contaminated equipment prior to its return to inventory, must be utilized in

order to prevent cross-contamination.

(11) Cytotoxic drugs. In addition to the minimum requirements for a pharmacy established

by rules of the Board, the following requirements are necessary for those pharmacies

that prepare cytotoxic drugs to insure the protection of the personnel involved.

(a) All cytotoxic drugs should be compounded in a vertical flow, Class II, biological

safety cabinet or an appropriate barrier isolator. Other preparations should not be

compounded in this cabinet.

(b) Personnel compounding cytotoxic drugs shall wear protective apparel as outlined

in the National Institute of Occupation Hazards (NIOSH) in addition to

appropriate compounding attire as described in USP 797.

(c) Appropriate safety and containment techniques for compounding cytotoxic drugs

shall be used in conjunction with the aseptic techniques required for preparing

sterile preparations.

(d) Disposal of cytotoxic waste shall comply with all applicable local, state, and

federal requirements.

(e) Written procedures for handling both major and minor spills of cytotoxic agents

must be developed and must be included in the policy and procedure manual.

(f) Prepared doses of cytotoxic drugs must be dispensed, labeled with proper

precautions inside and outside, and delivered in a manner to minimize the risk of

accidental rupture of the primary container.

(g) Disposal of cytotoxic and/or hazardous wastes. The pharmacist-in-charge is

responsible for assuring that there is a system for the disposal of cytotoxic and/or

infectious waste in a manner so as not to endanger the public health.

(12) Pharmacists shall not engage in the following:

(a) The compounding for human use of a pharmaceutical product that has been

withdrawn or removed from the market by the FDA because such drug product

or a component of such drug product has been found to be unsafe.

(b) The compounding of any pharmaceutical products that are essentially copies of

commercially available pharmaceutical products. However, this prohibition shall

not include:

1. The compounding of any commercially available product when there is a

change in the product ordered by the prescriber for an individual patient,

2. The compounding of a commercially available manufactured

pharmaceutical during times when the product is not available from the

manufacturer or wholesale distributor,

3. The compounding of a commercially manufactured pharmaceutical that

appears on the drug shortages list, or

4. The mixing of two or more commercially available products of which the

end product is a commercially available product.

(13) Practitioners who may lawfully compound pharmaceuticals for administering or

dispensing to their own patients pursuant to O.C.G.A. Section 26-4-130 shall comply

with all the provisions of this rule and other applicable Board laws, rules and

regulations.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.